Abstract
This article reviews randomized control trials (RCTs) published in 2006 of various medications evaluated for stroke patients. These trials were primarily efficacy studies. These included aggrenox (an antiplatelet agent), magnesium (to treat arterial spasm after an aneurysmal subarachnoid hemorrhage), NXY (a free radical trapping agent) and albumin which were both tested as a neuroprotectant, amphetamine (to aid motor recovery), fluoxetine (an anti-depressant and anxiolytic) and low molecular weight heparin (for prevention of deep vein thrombosis post-stroke).
Keywords: Randomized control trials, stroke, rehabilitation
Current Vascular Pharmacology
Title: Randomized Clinical Stroke Trials in 2006
Volume: 6 Issue: 1
Author(s): Meheroz H. Rabadi and John P. Blass
Affiliation:
Keywords: Randomized control trials, stroke, rehabilitation
Abstract: This article reviews randomized control trials (RCTs) published in 2006 of various medications evaluated for stroke patients. These trials were primarily efficacy studies. These included aggrenox (an antiplatelet agent), magnesium (to treat arterial spasm after an aneurysmal subarachnoid hemorrhage), NXY (a free radical trapping agent) and albumin which were both tested as a neuroprotectant, amphetamine (to aid motor recovery), fluoxetine (an anti-depressant and anxiolytic) and low molecular weight heparin (for prevention of deep vein thrombosis post-stroke).
Export Options
About this article
Cite this article as:
Rabadi H. Meheroz and Blass P. John, Randomized Clinical Stroke Trials in 2006, Current Vascular Pharmacology 2008; 6 (1) . https://dx.doi.org/10.2174/157016108783331259
DOI https://dx.doi.org/10.2174/157016108783331259 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gender Differences in Types, Frequency, Clinical Manifestations and Atherosclerotic Burden of Coronary Artery Anomalies
Reviews on Recent Clinical Trials Atherogenesis in Renal Patients: A Model of Vascular Disease?
Current Vascular Pharmacology Effects of Estrogens on Atherogenesis
Current Vascular Pharmacology Neurological Disorders in Pregnancy
Current Women`s Health Reviews Role of Diagnostic Ultrasound in Patient Selection for Stroke Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Indicators of Cardiovascular Risk in Metabolic Syndrome: Long Term Follow-up in Italian Patients
Current Vascular Pharmacology The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology Current Understanding of In-stent Restenosis and the Potential Benefit of Drug Eluting Stents
Current Drug Targets - Cardiovascular & Hematological Disorders Trefoil Factor Family (TFF) Peptides and their Different Roles in the Mucosal Innate Immune Defense and More: An Update
Current Medicinal Chemistry A Murine Model of Vasculitis Induced by Fungal Polysaccharide
Cardiovascular & Hematological Agents in Medicinal Chemistry Endothelium in Aortic Aneurysm Disease: New Insights
Current Medicinal Chemistry Roles of miRNA in Cardiovascular Development and Dysfunction
Current Medicinal Chemistry Infection-Associated Biomarkers of Inflammation in Atherosclerosis
Current Pharmaceutical Design Nimodipine Loaded PLGA Nanoparticles: Formulation Optimization Using Factorial Design,Characterization and In Vitro Evaluation
Current Drug Delivery Antibody Targeting of TGF-β in Cancer Patients
Current Pharmaceutical Biotechnology Coronary Stent Fracture: A Recently Appreciated Phenomenon with Clinical Relevance
Current Cardiology Reviews Targeting Cardiac Mast Cells: Pharmacological Modulation of the Local Renin-Angiotensin System
Current Pharmaceutical Design Cardiovascular Proteomics
Current Proteomics Clinical Studies with Paclitaxel - Eluting Stent Systems
Current Pharmaceutical Design Indoxyl Sulfate: A Candidate Target for the Prevention and Treatment of Cardiovascular Disease in Chronic Kidney Disease
Current Drug Targets